Summary: Amgen has developed ATOMIC, a machine learning (ML) model that analyzes large amounts of data and predicts which clinical trial sites are likely to enroll patients more quickly and effectively. ATOMIC leverages many forms of data, including demographic, geographic and real-world data to ensure faster and more representative participant enrollment. [...] This is an abstract of the document. To keep reading, click here and get access to the original version. Attachments Original document Permalink Disclaimer Amgen Inc. published this content on April 17, 2025 , and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT) , unedited and unaltered, on April 17, 2025 at 20:03 UTC . This is an abstract of the document. To keep reading, click here and get access to the original version. Attachments Original document Permalink Disclaimer Amgen Inc. published this content on April 17, 2025 , and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT) , unedited and unaltered, on April 17, 2025 at 20:03 UTC .
Amgen is a California-based multinational biopharmaceutical company that develops human therapeutics for the treatment of diseases including cancer and cardiovascular.